| 2007 |
Tünde Molnár |
Generics Medicines in the Centralised Procedure |
|
|
| 2007 |
Dr. Katrin Neubert |
Development of a rationale for deriving acceptance criteria for the validation of analytical methods in the pharmaceutical quality control |
|
|
| 2007 |
Angelika Ommeln |
Regulatory Data Analysis for the development of a database for country specific requirements |
|
|
| 2007 |
Michaela Oppold |
The opportunities of the new Regulation on medicinal products for paediatric use for existing marketing authorisations on the example of an off-patent drug substance |
|
|
| 2007 |
Dr. Zoran Pavlovski |
Essential regulatory requirements in the United States related to medical devices intended for human use |
|
|
| 2007 |
Wieland Peschel |
The regulatory challenge to improve the safety of Traditional Herbal Medicinal Products in Europe |
|
|
| 2007 |
Ariane Prochaska |
Assignment of GMP data - within application dossiers and during external inspections |
|
|
| 2007 |
Dr. Ursula Protin |
First experiences with Conditional Marketing Authorisations in the EU: requirements, obligations, initial experiences and perspectives |
|
|
| 2007 |
Susanne Rathmann |
Site Master File, a competent regulatory document |
|
|
| 2007 |
Dr. Herta Reile |
Implications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products Summary |
|
|
| 2007 |
Dr. Tatjana Reinholz |
Life cycle management of a marketed medicinal product in view of GMP and regulatory requirements and impact of Product Quality Reviews |
|
|
| 2007 |
Dr. Silvia Sanner |
Registration Procedures in South Africa |
|
|
| 2007 |
Dr. Peter Satter |
Assessment of potential similarity between orphan drugs |
|
|
| 2007 |
Dr. Katja Schepper |
Clinical requirements for the development of biosimilar products |
|
|
| 2007 |
Dr. Ursula Schickel |
The impact of the revised EU-legislation concerning particular needs of blind and partially-sighted patients and user testing a challenge for pharmaceutical companies with focus on Germany |
|
|
| 2007 |
Dr. Dirk Schmidt |
Impact and Consequences of the PAT Initiatives by FDA and EMEA on New Chemical Entity Synthesis |
|
|
| 2007 |
Dr. Sabine Schmitz |
Pharmaceutical Excipients Regulatory and GMP Requirements |
|
|
| 2007 |
Karin Schöpf |
Global Pharmaceutical Markets and the Influence of the International Organizations WHO and ICH |
|
|
| 2007 |
Dr. Desi W. Soegiarto |
Changes of Pharmacovigilance Requirements within the Scope of Volume 9A and Related EU Guidelines |
|
|
| 2007 |
Dr. Susanne Sommer |
Package Leaflets: Testing and harmonisation in relation to the overall business process in regulatory procedures - An example of the impact of changing regulatory requirements |
|
|